Antiangiogenic plasma activity in patients with systemic sclerosis

Arthritis and Rheumatism

Volumn 56, Issue 10, 2007, Pages 3448-3458

  Mulligan Kehoe, Mary Jo ^a   Drinane, Mary C ^a   Mollmark, Jessica ^a   Casciola Rosen, Livia ^b   Hummers, Laura K ^b   Hall, Amy ^a   Rosen, Antony ^b   Wigley, Fredrick M ^b   Simons, Michael ^a,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; GRANZYME B; PLASMIN; PLASMINOGEN;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CATTLE; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MALE; MICROVASCULARIZATION; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADULT; ANGIOGENESIS INHIBITORS; CELL MOVEMENT; ENDOTHELIAL CELLS; FEMALE; GRANZYMES; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; WOUND HEALING;

EID: 35348891629     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22861     Document Type: Article

References (58)

1. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004;364: 603-10.
2. LeRoy EC. Systemic sclerosis: a vascular perspective [review]. Rheum Dis Clin North Am 1996;22:675-94.
3. Wigley FM, Flavahan NA. Raynaud's phenomenon [review]. Rheum Dis Clin North Am 1996;22:765-81.
4. Simons M. Angiogenesis: where do we stand now? [review]. Circulation 2005;111:1556-66.
5. Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease [review]. Nat Rev Drug Discov 2003;2:863-71.
6. Lu H, Dhanabel M, Volk R, Waterman MJ, Ramchandran R, Knebelmann B, et al. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem Biophys Res Commun 1999;258:668-73.
7. Staton CA, Lewis CE. Angiogenesis inhibitors found within the haemostasis pathway [review]. J Cell Mol Med 2005;9:286-302.
8. Kahaleh MB, LeRoy EC. Endothelial injury in scleroderma: a protease mechanism. J Lab Clin Med 1983;101:553-60.
9. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med 1979;149:1326-35.
10. Ulanet DB, Wigley FM, Gelber AC, Rosen A. Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthritis Rheum 2003;49:85-92.
11. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:1104-17.
12. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, et al. Kringle domains of human angiostatin: characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996; 271:29461-7.
13. Linde V, Nielsen LS, Foster DC, Petersen LC. Elimination of the Cys558-Cys566 bond in Lys78-plasminogen: effect on activation and fibrin interaction. Eur J Biochem 1998;251:472-9.
14. Ihn H. The role of TGF-β signaling in the pathogenesis of fibrosis in scleroderma. Arch Immunol Ther Exp (Warsz) 2002;50:325-31.
15. Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K. Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. J Invest Dermatol 2005;124:324-30.
16. Myohanen H, Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen [review]. Cell Mol Life Sci 2004;61:2840-58.
17. Lijnen HR, Ugwu F, Bini A, Collen D. Generation of an angiosta-tin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998;37:4699-702.
18. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999;274:29568-71.
19. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272:28823-5.
20. Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CN, Hogg PJ. Generation of angiostatin by reduction and proteolysis of plasmin: catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem 1997;272:20641-5.
21. Stathakis P, Lay AJ, Fitzgerald M, Schlieker C, Matthias LJ, Hogg PJ. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. J Biol Chem 1999;274:8910-6.
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
23. Drinane M, Walsh J, Mollmark J, Simons M, Mulligan-Kehoe MJ. The anti-angiogenic activity of rPAI-1(23) inhibits fibroblast growth factor-2 functions. J Biol Chem 2006;281:33336-44.
24. Gabbiani G, Gabbiani F, Heimark RL, Schwartz SM. Organization of actin cytoskeleton during early endothelial regeneration in vitro. J Cell Sci 1984;66:39-50.
25. Gao Y, Li M, Chen W, Simons M. Synectin, syndecan 4 cytoplasmic domain binding PDZ protein, inhibits cell migration. J Cell Physiol 2000;184:373-9.
26. Horowitz A, Tkachenko E, Simons M. Fibroblast growth factor-specific modulation of cellular response by syndecan-4. J Cell Biol 2002;157:715-25.
27. Lee JG, Kay EP. Cross-talk among Rho GTPases acting downstream of PI 3-kinase induces mesenchymal transformation of corneal endothelial cells mediated by FGF-2. Invest Ophthalmol Vis Sci 2006;47:2358-68.
28. Tang S, Morgan KG, Parker C, Ware JA. Requirement for protein kinase C theta for cell cycle progression and formation of actin stress fibers and filopodia in vascular endothelial cells. J Biol Chem 1997;272:28704-11.
29. Wahl ML, Grant DS. Effects of microenvironmental extracellular pH and extracellular matrix proteins on angiostatin's activity and on intracellular pH. Gen Pharmacol 2000;35:277-85.
30. Wahl ML, Owen CS, Grant DS. Angiostatin induces intracellular acidosis and anoikis in endothelial cells at a tumor-like low pH. Endothelium 2002;9:205-16.
31. Andrade F, Roy S, Nicholson D, Thornberry N, Rosen A, Casciola-Rosen L. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity 1998;8:451-60.
32. Schachna L, Wigley FM, Morris S, Gelber AC, Rosen A, Casciola-Rosen L. Recognition of granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum 2002;46:1873-84.
33. Ulanet DB, Flavahan NA, Casciola-Rosen L, Rosen A. Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: insights into the association of specific autoantibodies with distinct disease phenotypes. Arthritis Rheum 2004;50:233-41.
34. Konttinen YT, Mackiewicz Z, Ruuttila P, Ceponis A, Sukura A, Povilenaite D, et al. Vascular damage and lack of angiogenesis in systemic sclerosis skin. Clin Rheumatol 2003;22:196-202.
35. Koch AE, Litvak MA, Burrows JC, Polverini PJ. Decreased monocyte-mediated angiogenesis in scleroderma. Clin Immunol Immunopathol 1992;64:153-60.
36. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002;4:R11.
37. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000;43:889-93.
38. Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska A. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm 2005;2005:144-9.
39. Majewski S, Skopinska-Rozewska E, Jablonska S, Polakowski I, Pawinska M, Marczak M, et al. Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. Arthritis Rheum 1985;28:1133-9.
40. Giusti B, Fibbi G, Margheri F, Serrati S, Rossi L, Poggi F, et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 2006;8:R115.
41. Mulligan-Kehoe MJ, Simons M. Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep 2007;9:173-9.
42. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Increased expression levels of integrin αvβ5 on scleroderma fibroblasts. Am J Pathol 2004;164:1275-92.
43. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 2002;99:3908-13.
44. Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, et al. Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007;56: 334-44.
45. Verrecchia F, Laboureau J, Verola O, Roos N, Porcher R, Bruneval P, et al. Skin involvement in scleroderma: where histological and clinical scores meet. Rheumatology (Oxford) 2007;46: 833-41.
46. Herouy Y, Aizpurua J, Stetter C, Dichmann S, Idzko M, Hofmann C, et al. The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis. J Cutan Pathol 2001;28:291-7.
47. Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, β-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55: 122-7.
48. Trifiletti A, Bartolone S, Scamardi R, Pizzoleo MA, Sottilotta G, Larosa D, et al. Evaluation of haemostatic parameters and circadian variations of the haemostatic system in patients with systemic sclerosis and Raynaud's phenomenon. Panminerva Med 2000;42: 7-9.
49. Cockell CS, Marshall JM, Dawson KM, Cederholm-Williams SA, Ponting CP. Evidence that the conformation of unliganded human plasminogen is maintained via an intramolecular interaction between the lysine-binding site of kringle 5 and the N-terminal peptide. Biochem J 1998;333(Pt 1):99-105.
50. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem 1982;257:2912-9.
51. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
52. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004;112: 496-507.
53. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
54. Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J, Shi GY, et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci U S A 1999;96:5728-33.
55. Wang H, Schultz R, Hong J, Cundiff DL, Jiang K, Soff GA. Cell surface-dependent generation of angiostatin4.5. Cancer Res 2004; 64:162-8.
56. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999;190:815-25.
57. Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, Timpl R. Endostatin derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and antiangiogenic activity. J Mol Biol 2000;301:1179-90.
58. Maeshima Y, Sudhaker A, Lively JC, Ueki K, Kharbanda S, Kahn CR, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002;295:140-3.